SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Cannabis Science Inc (OTCMKTS:CBIS) was a notable decliner during Friday’s trading session declining by 2% on relatively high volumes, which were 0.8 times the daily average turnover. Bears seem to holding the upper hand at the current moment as the stock has been forming lower tops and lower bottoms indicative of the strong bearish momentum. Cannabis Science currently trades below all important moving averages, which is considered to be a bearish signal. The momentum oscillators show no signs of a reversal. The stock trades close to its 52-week low. Traders believe the stock could head to levels of $0.0150 in the near term.

CBIS

Cannabis Science Inc (OTCMKTS:CBIS), better known for its world-class products in cannabis field, announced the release of its cannabinoid-formulated capsule product line in California market. As per the reports, it has decided to release three formulations CBD, Sativa and Indica at first.

To make sure that maximum people can get benefitted from it, Cannabis Science will release them in 25mg, 50mg and 100 mg doses. Once the demand increases, it will think of introducing more dose options in the future, details of which will be announced at a later date.

Management Call

The senior management team of the company is delighted to make this announcement and hopes that launch of this new capsule line will help the Cannabis Science solidify its market position. According to Raymond C. Dabney, Co-Founder, CEO & President, Cannabis Science Inc (OTCMKTS:CBIS), it’s great to launch the next Cannabis Science product on the market.

The R&D and production teams have ensured that the delivery mechanism of these capsules remains easy to understand. It’s the biggest reason they have become popular among users within a short duration since their launch.

The management team doesn’t want to leave any stone unturned when it comes to distributing these capsules. To begin with, distribution team has initiated its efforts in California states. A host of dispensaries are being contacted on a regular basis to ensure that enough quantity of these capsules is available throughout the state.

To give promotion efforts newer heights, the company has decided to present Sativa, Indica and CBD at the sought after Emerald Cup event on December 12, 2015, and December 13, 2015, in Santa Rosa, California. These capsules can be used for multiple applications varying from neurological treatments to inflammation reduction and normal pain. Further updates about the response that Cannabis Science receives at the Emerald Cup will be announced in the near future.